Home/Pipeline/Parkinson's Disease Portfolio (Platform-derived)

Parkinson's Disease Portfolio (Platform-derived)

Parkinson's Disease

Not Disclosed (Likely Preclinical/Early Clinical)Active

Key Facts

Indication

Parkinson's Disease

Phase

Not Disclosed (Likely Preclinical/Early Clinical)

Status

Active

Company

WD Pharmaceutical

About WD Pharmaceutical

A biotech company developing proprietary drug/device delivery platforms (UGi-Pump® and AcuSiS®) to improve drug absorption and administration for challenging patient populations.

View full company profile

Therapeutic Areas

Neurology (Parkinson's Disease)Cardiovascular Infectious Disease

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active
golexanolone	Umecrine Cognition	Preclinical	Active